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Metabolic Complications among Korean Patients with HIV 
Infection: The Korea HIV/AIDS Cohort Study
Currently, metabolic complications are the most common problem among human 
immunodeficiency virus (HIV)-infected patients, with a high incidence. However, there 
have been very few studies regarding metabolic abnormalities published in Asia, especially 
in Korea. This cross-sectional study was performed to investigate the prevalence of and risk 
factors for metabolic abnormalities in 1,096 HIV-infected patients of the Korea HIV/AIDS 
cohort study enrolled from 19 hospitals between 2006 and 2013. Data at entry to cohort 
were analyzed. As a result, the median age of the 1,096 enrolled subjects was 46 years, 
and most patients were men (92.8%). The metabolic profiles of the patients were as 
follows: median weight was 63.8 kg, median body mass index (BMI) was 22.2 kg/m2, and 
16.4% of the patients had a BMI over 25 kg/m2. A total of 5.5% of the patients had 
abdominal obesity (waist/hip ratio ≥ 1 in men, ≥ 0.85 in women). Increased levels of 
fasting glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, and 
triglycerides were present in 10.4%, 6.0%, 5.5%, and 32.1% of the patients. Decreased 
high-density lipoprotein (HDL) cholesterol levels were observed in 44.2% of the patients. 
High systolic blood pressure was present in 14.3% of the patients. In multivariate analysis, 
high BMI and the use of protease inhibitors (PIs) were risk factors for dyslipidemia in HIV-
infected patients. In conclusion, proper diagnosis and management should be offered for 
the prevalent metabolic complications of Korean HIV-infected patients. Further studies on 
risk factors for metabolic complications are needed.
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INTRODUCTION
The introduction of highly active antiretroviral therapy (HAART) for the treatment of 
human immunodeficiency virus (HIV) infection changed the characteristics of HIV in-
fection, from a fatal disease to a chronic manageable infectious disease (1). However, 
as the life expectancy of HIV-infected patients increased, lifestyle-related comorbidi-
ties such as cardiovascular disease (CVD), diabetes, and hyperlipidemia began to emerge 
as a problematic issue and challenge in the treatment of HIV infection. Furthermore, 
antiretroviral drugs have the potential to induce many adverse drug reactions as well 
as drug-drug interactions with medications administered for the treatment of other 
comorbidities (2).
 Long-term metabolic complications induced by antiretroviral drugs include osteo-
porosis, lipodystrophy, dyslipidemia, hyperglycemia, hypertension, and metabolic syn-
drome, among others. These complications may be risk factors for cerebral vascular 
disease and coronary artery disease, and may contribute to the morbidity and mortali-
ty of these diseases. Recent studies have reported a higher prevalence of these diseases 
in HIV-infected patients than in the general population (3,4).
 Differences in the prevalence of these long-term metabolic complications have been 
observed across previous studies, because each of the studies was performed in a dif-
ferent population and used different diagnostic criteria (5). Choe et al. (6) published a 
study evaluating the incidence of metabolic complications in a Korean population of 
HIV-infected patients in 2004. The study analyzed 66 HIV-infected patients and found 
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an incidence of metabolic complications of 20.3%. In detail, the 
incidence of hypertriglyceridemia, hypercholesterolemia, hy-
perglycemia, and diabetes was 12.3%, 5.8%, 1.4%, and 4.3%, re-
spectively.
 To date, several studies have investigated the prevalence of 
metabolic complications in HIV-infected patients in Korea. How-
ever, these studies were limited by small sample sizes, and each 
study did not analyze metabolic parameters comprehensively 
(6-11). The purpose of the present study was to identify the prev-
alence of and evaluate the risk factors for metabolic complica-
tions in HIV-infected patients in Korea.
MATERIALS AND METHODS
Study population and design
Participants in this prospective cross-sectional study were HIV-
infected subjects who visited 19 hospitals affiliated with the Ko-
rean HIV/AIDS Cohort from December 2006 to July 2013. The 
study protocol was approved by the Institutional Review Board 
of each of the participating hospitals. All participants were older 
than 18 years and provided informed consent prior to enroll-
ment. Data at entry to cohort were used for analyses. The preva-
lence of metabolic abnormalities was calculated, and the rates 
of metabolic abnormalities were compared with data reported 
for the general population. The rates of metabolic abnormali-
ties were compared between treatment-naïve and treatment-
experienced subjects. In addition, a case-control study was per-
formed to identify risk factors for dyslipidemia.
Data collection
Demographic and clinical characteristics were obtained for all 
participants. Biologic data such as age, sex, race, body weight, 
body mass index (BMI), waist circumference (WC), waist/hip 
ratio, and blood pressure were collected. Regarding comorbidi-
ties, history of hypertension, diabetes, dyslipidemia, CVD, smok-
ing history, and family history were collected. In terms of histo-
ry related to HIV infection, sexual habits, history of exposure 
route of HIV, time of entry to cohort, time of diagnosis, clinical 
classification guided by the Centers for Disease Control and Pre-
vention, baseline CD4+ T-cell counts, baseline HIV viral loads, 
antiviral treatment status, and antiretroviral regimen were col-
lected. Laboratory data related to metabolic complications such 
as fasting glucose, total cholesterol, high-density lipoprotein 
(HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, 
and triglycerides were evaluated. To assess cardiovascular risk, 
the Framingham risk score (FRS) was calculated (12).
Definitions
Hyperglycemia is defined as serum fasting glucose ≥ 126 mg/
dL (13). Hypercholesterolemia is defined as serum total choles-
terol ≥ 240 mg/dL. Hypoalphalipoproteinemia is defined as se-
rum HDL-cholesterol < 40 mg/dL. Hyper LDL-cholesterolemia 
is defined as serum LDL-cholesterol ≥ 160 mg/dL. Hypertriglyc-
eridemia is defined as serum triglycerides ≥ 200 mg/dL (14). 
High and low BMI are defined as BMI > 25 and < 18.5, respec-
tively (15). Dyslipidemia was defined as the presence of one or 
more of hypercholesterolemia, hyper LDL-cholesterolemia, hy-
poalphalipoproteinemia, and hypertriglyceridemia (16). Lipo-
dystrophy was defined as the presence of peripheral lipoatro-
phy or central fat accumulation subjectively measured by stan-
dardized physical examination procedure (17). The FRS is the 
most commonly used tool for prediction of cardiovascular risk, 
and is calculated using variables including age, sex, total cho-
lesterol, HDL-cholesterol, hypertension, hypertension treatment, 
diabetes mellitus, and current smoking. Subjects were classified 
as having a very low, low, moderate, or high 10-year coronary 
risk in accordance with the Framingham equation (<10%, 10%–
15%, 16%–20%, and > 20%, respectively) (18).
Data analysis
Continuous variables were expressed as mean or median (in-
terquartile range) and compared using Student’s t-test if the vari-
ables followed a normal distribution. Continuous variables with 
skewed distribution were compared using the Mann-Whitney 
U test. Categorical variables were compared using the χ2 test. 
Variables with a P value less than 0.05 on univariate analysis 
were included in the logistic regression model for multivariate 
analysis for predicting risk factors for dyslipidemia. All statisti-
cal analyses were performed using SAS 9.2 (SAS Institute Inc., 
Cary, NC, USA). P values less than 0.05 were considered statisti-
cally significant.
Ethics statement
The study was approved by the Institutional Review Board of 
the Yonsei University Health System Clinical Trial Center and 
proceeded with getting informed consent from all patients par-
ticipating in the study (Study No. 4-2006-0158).
RESULTS
A total of 1,096 patients were eligible for inclusion in this study. 
The median age of participants was 46 years, and the proportion 
of men was 92.8%. Almost all participants were Korean (99.1%), 
and the most frequent exposure route of HIV infection was sex-
ual contact (87%). The proportion of intravenous drug use was 
0.4%. The median baseline CD4+ T-cell count of participants was 
235 cells/μL, and the proportion of treatment-naïve patients was 
35.5%. The most commonly used antiretroviral regimen was a 
protease inhibitor (PI)-based regimen (40.4%) (Table 1).
 The prevalence of metabolic complications in all HIV-infect-
ed patients in the cohort was as follows. The prevalence of obe-
sity based on BMI, obesity based on waist/hip ratio (waist/hip 
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ratio ≥ 1 in men, ≥ 0.85 in women), hyperglycemia, hypercho-
lesterolemia, hypoalphalipoproteinemia, hyper LDL-cholester-
olemia, and hypertriglyceridemia were 16.4%, 19.0%, 10.4%, 6.0%, 
44.2%, 5.5%, and 32.1%, respectively (Table 1). Among metabol-
ic parameters, median serum total cholesterol (155 [48–297] vs. 
176 [11–364] mg/dL; P < 0.001), HDL-cholesterol (38 [4–137] 
vs. 45 [10–177] mg/dL; P < 0.001), and triglycerides (155 [14–636] 
vs. 202 [18–1,040] mg/dL; P < 0.001) were significantly higher in 
treatment-experienced patients (Table 2). Additionally, the pro-
portion of hypercholesterolemia (2.7% vs. 7.7%; P = 0.008) and 
hypertriglyceridemia (23.7% vs. 37.2%; P < 0.001) were signifi-
cantly higher in treatment-experienced patients than in treat-
ment naïve patients. Other metabolic parameters did not show 
statistically significant differences between the 2 patient groups.
 To analyze the risk factors for dyslipidemia in HIV-infected 
patients, univariate and multivariate analyses were performed. 
Comparison of the patient group without dyslipidemia and the 
patient group with dyslipidemia showed that the dyslipidemia 
group had older age (47.1 vs. 44.5 years; P = 0.005), higher pro-
portion of high CD4+ T-cell counts (P = 0.010) and low HIV viral 
loads (P < 0.001); higher proportion of PI-based regimen (64.0% 
vs. 47.9%; P < 0.001); higher BMI (23.42 vs. 21.76 kg/m2; P = 0.001); 
larger WC (85.2 vs. 79.7 cm; P < 0.001); and higher rate of obesi-
ty (9.0% vs. 2.8%; P = 0.014) and high systolic blood pressure 
(21.3% vs. 12.2%; P = 0.006) than the group without dyslipidemia. 
However, high BMI (odds ratio [OR], 6.839; 95% confidence in-
terval [CI], 2.673–17.495; P < 0.001) and the use of PI-based reg-
imen (OR, 2.868; 95% CI, 1.419–5.797; P = 0.003) were significant 
risk factors for dyslipidemia in multivariate analysis (Table 3).
 
DISCUSSION
As the life expectancy of HIV-infected patients is increasing, met-
abolic complications are emerging as an issue of concern in man-
aging HIV infections. This study evaluated the prevalence and 
characteristics of metabolic complications in HIV-infected Ko-
reans.
 As mentioned above, the prevalence of obesity based on BMI, 
obesity based on waist/hip ratio, hyperglycemia, hypercholes-
terolemia, hypoalphalipoproteinemia, hyper LDL-cholesterol-
emia, and hypertriglyceridemia were 16.4%, 19.0%, 10.4%, 6.0%, 
44.2%, 5.5%, and 32.1%, respectively. These results are similar 
to the findings of a recent study conducted in an Asian popula-
tion (19), but, compared to a previous Korean study (6), the prev-
alence of metabolic complications was relatively high. This dif-
ference seems to be the result of the difference in the study pe-
riod between our study and the former study. Over a decade, 
there have been many changes in treatment trends; therefore, 
characteristics of HIV-infected patients have changed. When 
comparing the metabolic parameters between patient groups 
depending on the presence or absence of antiretroviral treatment, 
Table 1. Baseline characteristics of HIV-infected patients in this study
Variables HIV-infected patients (n = 1,096)
Age at entry to cohort, yr
   Median (range) 46 (20–83)
   20–29 96 (8.8)
   30–39 266 (24.3)
   40–49 325 (29.7)
   50–59 260 (23.7)
  ≥ 60 149 (13.6)
Sex  
   Male 1,017 (92.8)
Race  
   Korean 1,086 (99.1)
   Asian 10 (0.9)
Reported exposure category  
   Sexual contact 953 (87.0)
   Reception of blood/product 25 (2.3)
   IDU 4 (0.4)
   Other 61 (5.6)
Sexual habit  
   Homosexual 353/958 (36.8)
   Heterosexual 368/958 (44.6)
   Bisexual 83/958 (8.6)
   Other 154/958 (16.0)
First year diagnosed with HIV  
   Before 1991 4/1,029 (0.4)
   1991–1995 19/1,029 (1.8)
   1996–2000 50/1,029 (4.9)
   2001–2005 276/1,029 (26.8)
   2006–2010 560/1,029 (54.4)
   After 2010 120/1,029 (11.7)
CDC clinical classification for HIV infection  
   Category A 398/1,095 (36.5)
   Category B 286/1,095 (26.1)
   Category C 311/1,095 (28.4)
Baseline CD4+ T-cell count, cells/μL  
   Median (range) 235 (1–1,699)
  < 50 198/750 (26.4)
   50–199 186/750 (24.8)
   200–499 278/750 (37.1)
  ≥ 500 88/750 (11.7)
Baseline HIV viral loads, copies/mL  
   Median (range) 3.9 × 105 (0–7.5 × 107)
   Not detected 33/745 (4.4)
  < 400 333/745 (44.7)
   400–9,999 57/745 (7.7)
   10,000–99,999 146/745 (19.6)
  ≥ 100,000 176/745 (23.6)
Treatment  
   Treatment-naïve 387/1,091 (35.5)
   Treatment-experienced 704/1,091 (64.5)
Antiretroviral treatment at entry to cohort  
   Not on treatment 416/1,084 (38.4)
   2 NRTIs+PI 438/1,084 (40.4)
   2 NRTIs+NNRTI 196/1,084 (18.1)
   2 NRTIs+II 7/1,084 (0.6)
   3 NRTIs 1/1,084 (0.1)
   Combinations without NRTIs 4/1,084 (0.4)
   Other 22/1,084 (2.0)
HIV = human immunodeficiency virus, IDU = intravenous drug use, CDC = Centers 
for Disease Control and Prevention, NRTI = nucleoside analogue reverse transcrip-
tase inhibitor, PI = protease inhibitor, NNRTI = non-nucleoside reverse transcriptase 
inhibitor, II = integrase inhibitor.
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Table 2. Comparisons of metabolic parameters between treatment-naïve patients and treatment-experienced patients
Variables Total (n = 1,091) Treatment-naïve (n = 387) Treatment-experienced (n = 704) P value
Weight, kg
   Median (range) 63.8 (36.4–122.5) 64.4 (39–107) 63.4 (36.4–122.5) 0.190*
BMI, kg/m2
   Median (range) 22.2 (14.5–37.8) 22.2 (14.8–33.8) 22.14 (14.5–37.8) 0.817*
  > 25 140/856 (16.4) 56/318 (17.6) 84/537 (15.6) 0.452†
WC, cm
   Median (range) 82.0 (60.0–120.0) 81.2 (65–118) 82.4 (60.0–120.0) 0.176*
   Abdominal obesity 85/447 (19.0) 28/154 (18.2) 57/293 (19.5) 0.745†
Waist/hip ratio
   Median (range) 0.87 (0.71–1.21) 0.87 (0.73–1.21) 0.88 (0.71–1.16) 0.160*
   Abdominal obesity 23/417 (5.5) 7/146 (4.8) 16/273 (5.9) 0.648†
Fasting glucose, mg/dL
   Median (range) 103 (62–432) 101 (62–346) 104 (64–432) 0.240*
  ≥ 126 82/787 (10.4) 22/265 (8.3) 60/522 (11.5) 0.166†
Total cholesterol, mg/dL
   Median (range) 169 (11–364) 155 (48–297) 176 (11–364) < 0.001*
  ≥ 280 12/997 (1.2) 2/332 (0.6) 10/663 (1.5) 0.008†
   240–279 48/997 (4.8) 7/332 (2.1) 41/663 (6.2) -
HDL-cholesterol, mg/dL
   Median (range) 43 (4–177) 38 (4–137) 45 (10–177) < 0.001*
  < 40 337/763 (44.2) 148/254 (58.3) 189/507 (37.3) < 0.001†
LDL-cholesterol, mg/dL
   Median (range) 101 (10–1,236) 98 (10–623) 103 (11–1,236) 0.313*
  ≥ 190 13/688 (1.9) 3/230 (1.3) 10/455 (2.2) 0.593†
   160–189 25/688 (3.6) 7/230 (3.0) 18/455 (4.0) -
Triglycerides, mg/dL
   Median (range) 186 (14–1,040) 155 (14–636) 202 (18–1,040) < 0.001*
  ≥ 500 27/872 (2.5) 2/279 (0.7) 25/589 (4.2) < 0.001†
   200–499 258/872 (29.6) 64/279 (22.9) 194/589 (32.9) -
Systolic blood pressure, mmHg
   Median (range) 124 (82–205) 123 (82–173) 125 (90–205) 0.102*
  > 160 21/742 (2.8) 8/251 (3.2) 13/491 (2.6) 0.191†
   140–159 97/742 (11.5) 22/251 (8.8) 65/491 (13.2) -
Smoking history 649/1,044 (62.2) 238/366 (64.9) 410/676 (60.4) 0.239†
   Current smoking 466/1,044 (44.6) 191/366 (52.2) 274/676 (40.5)
Underlying disease
   Hypertension 112/1,087 (10.3) 37/383 (9.7) 75/690 (10.9) 0.535†
      On antihypertensive treatment 97/1,087 (8.9) 33/383 (8.6) 64/690 (9.3)
   Dyslipidemia 96/1,081 (8.9) 10/382 (2.6) 86/686 (12.4) < 0.001†
      On dyslipidemia treatment 80/1,081 (7.4) 8/382 (2.1) 72/686 (10.5)
   Diabetes mellitus 71/1,088 (6.5) 23/383 (6.0) 48/691 (6.9) 0.552†
      On diabetes treatment 68/1,088 (6.2) 23/383 (6.0) 45/691 (6.5)
   Lipodystrophy 28/1,089 (2.6) 0/385 (0) 28/693 (4.0) < 0.001†
   CVD
      Angina pectoris 3/1,064 (0.3) 0/381 (0) 3/678 (0.4) 0.299†
      Myocardial infarction 3/1,064 (0.3) 0/381 (0) 3/678 (0.4) 0.165†
      Stroke 12/1,064 (1.1) 5/381 (1.3) 8/678 (1.2) 0.295†
Family history
   Hypertension 262/1,093 (23.9) 87/386 (22.5) 175/704 (24.9) 0.525†
   Diabetes mellitus 213/1,093 (19.5) 67/386 (17.4) 146/704 (20.7) 0.308†
   Dyslipidemia 12/1,093 (1.1) 2/386 (0.5) 10/704 (1.4) 0.223†
   Ischemic heart disease 43/1,093 (3.9) 10/386 (2.6) 33/704(4.7) 0.167†
FRS
   Median 7.13 (0–31) 6.61 (0–31) 7.4 (0–31) 0.194*
   Low risk 409/558 (87.3) 147/192 (76.6) 262/366 (71.6) 0.419†
   Moderate risk 122/588 (11.1) 36/192 (18.8) 86/366 (23.5) -
   High risk 27/558 (2.5) 9/192 (4.7) 18/366 (4.9) -
The data were expressed as median (interquartile range) or number (percentage).
BMI = body mass index, WC = waist circumference, HDL = high-density lipoprotein, LDL = low-density lipoprotein, CVD = cardiovascular disease, FRS = Framingham risk score.
*Mann-Whitney U-test, median (interquartile range); †Pearson’s χ2-test.
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median total cholesterol, HDL-cholesterol, and triglyceride lev-
els were high among patients who received antiretroviral thera-
py. Furthermore, the prevalence of dyslipidemia and lipodys-
trophy among comorbidities were also significantly high in the 
patients receiving antiretroviral treatment. This result is similar 
to previous study findings. Jantarapakde et al. (19) reported a 
higher prevalence of lipodystrophy and median total cholester-
ol, HDL-cholesterol, and triglycerides in patients who had re-
ceived antiretroviral therapy. Moreover, increases in mean total 
cholesterol, HDL-cholesterol, and triglyceride levels were ob-
served as the duration of antiretroviral therapy increased in pre-
vious studies in Asian patients (20,21). Therefore, in consider-
ation of these studies, it can be presumed that antiretroviral ther-
apy influenced the prevalence of metabolic complications.
 This is thought to be the result of the combination of the cata-
bolic characteristics of HIV infection, lipodystrophy due to anti-
retroviral treatment, and the effects on metabolic profiles of an-
tiretroviral therapy. In this cohort, 38.4% of the patients were 
not undergoing treatment for HIV infection at entry into the co-
hort, but some antiretroviral regimens such as PIs could cause 
dyslipidemia.
 In comparison of the patient groups depending on the pres-
ence or absence of dyslipidemia, high BMI and the use of a PI-
based regimen as antiretroviral therapy were significant risk fac-
tors for dyslipidemia on multivariate analysis. BMI is associated 
with the prevalence of dyslipidemia; and a Japanese study con-
ducted by Ishikawa-Takata et al. (22) showed Japanese had a 
higher prevalence of dyslipidemia than Caucasian, even with 
low BMI. Since this study was also conducted on Asian, the re-
sults can also be referred to the Japanese study. The association 
between metabolic syndrome and PI exposure was frequently 
mentioned in previous studies (23,24). In addition, dyslipidemia 
might be associated with lipodystrophy in HIV-infected patients. 
Fat accumulation, a type of lipodystrophy, can be induced by PI 
treatment (25). However, the results of a recently reported ran-
domized controlled study indicated that there was no difference 
Table 3. Comparison and multivariate analysis of risk factors for dyslipidemia in HIV-infected patients
Variables
Patients without dyslipidemia 
(n = 433)
Patients with dyslipidemia 
(n = 247)
P value OR (95% CI); P value
Age, yr 44.5 (20–82) 47.1 (25–81) 0.005* -
Male 408/433 (94.2) 230/247 (93.1) 0.563† -
Race
   Korean 428/433 (98.8) 246/247 (99.6) 0.315† -
   Asian 5/433 (1.2) 1/247 (0.4) - -
CD4+ cell counts, cells/μL 225 (1–1,584) 261 (2–1,699) 0.105*
  < 50 19/349 (5.4) 2/216 (0.9) 0.010† -
   50–199 64/349 (18.3) 37/216 (17.1) - -
   200–499 182/349 (52.1) 106/216 (49.1) - -
  ≥ 500 84/349 (24.1) 71/216 (32.9) - -
HIV viral loads, copies/mL 4.24 × 105 3.07 × 105 0.731‡
   Not detected 17/339 (5.0) 21/210 (10.0) < 0.001† -
  < 400 152/339 (44.8) 122/210 (58.1) - -
   400–9,999 54/339 (15.9) 25/210 (11.9) - -
   10,000–99,999 72/339 (21.2) 22/210 (10.5) - -
   > 100,000 44/339 (13.0) 20/210 (9.5) - -
HAART regimen
   PI treatment 198/413 (47.9) 153/239 (64.0) < 0.001† 2.868 (1.419–5.797)§; 0.003
   NNRTI treatment 212/424 (28.5) 79/247 (32.0) 0.347† -
Smoking 263/417 (63.1) 152/236 (64.4) 0.931† -
BMI, kg/m2 21.76 (15.20–31.74) 23.42 (16.40–37.80) < 0.001*
   > 25 54/366 (14.8) 55/210 (26.2) 0.001† 6.839 (2.673–17.495)§; < 0.001
WC, cm 79.7 (60–107) 85.2 (68–120) < 0.001* -
Obesity (waist/hip ratio) 6/211 (2.8) 11/122 (9.0) 0.014† -
Systolic blood pressure, mmHg 122 (92–181) 128 (95–205) 0.001* 
   > 140 40/327 (12.2) 42/197 (21.3) 0.006† -
Fasting glucose, mg/dL 102 (62–432) 107 (70–358) 0.060*
  ≥ 126 28/349 (8.0) 29/200 (14.5) 0.017† -
FRS 5.81 (0–31) 9.05 (0–31) < 0.001*
   Low risk 255/320 (79.7) 123/190 (64.7) < 0.001† -
   Intermediate to high risk 65/320 (20.3) 67/190 (35.3) - -
The data were expressed as median (interquartile range) or number (percentage) or mean.
HIV = human immunodeficiency virus, OR = odds ratio, CI = confidence interval, HAART = highly active antiretroviral therapy, PI = protease inhibitor, NNRTI = non-nucleoside 
reverse transcriptase inhibitor, BMI = body mass index, WC = waist circumference, FRS = Framingham risk score.
*Mann-Whitney U-test, median (interquartile range); †Pearson’s χ2-test; ‡Student’s t-test; §Logistic regression analysis.
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in the appearance of fat accumulation between treatment with 
PIs and other classes of antiretroviral drugs (26). In our cohort, 
other classes of antiretroviral drug such as non-nucleoside re-
verse transcriptase inhibitors (NNRTIs) did not show a signifi-
cant correlation with the appearance of dyslipidemia. However, 
because about 40% of HIV-infected patients were receiving PI-
based regimens, and the percentage of those receiving ritona-
vir-boosted lopinavir (22.1%), which is well known to induce 
dyslipidemia, was relatively high, the difference between the 
previous study and this study can be explained through this fac-
tor (data not shown).
 CVD is an important predictor of mortality in the general pop-
ulation, and dyslipidemia is an important risk factor for the oc-
currence of CVD (27). In a previous cohort study of 4,061 patients, 
dyslipidemia in HIV-infected patients was found to be a major 
risk factor for CVD (28). Therefore, dyslipidemia caused by HIV 
infection and antiretroviral agents increases long-term mortali-
ty by increasing the risk of CVD. Additionally, HIV infection it-
self is a risk factor for the development of CVD (3).
 This study has some limitations. First, the number of patients 
was small, and it limits our study results. Second, because of 
the cross-sectional design of this study, we could not evaluate 
the incidence of and associated factors for metabolic complica-
tions. Third, the distribution of antiretroviral regimens was not 
even because of the observational study design. Additionally, 
because we analyzed data from 2006 to 2013, this study could 
not reflect the current situation of Korea. Especially, single tab-
let regimens with integrase strand transfer inhibitor are intro-
duced into Korea in 2014, and HAART regimens including inte-
grase strand transfer inhibitor are more commonly used. That 
might change the prevalence of metabolic complications in Ko-
rea since 2014. Finally, there were significant missing values for 
some important variables such as FRS, smoking history, and so on.
 In conclusion, HIV-infected Koreans had higher serum tri-
glyceride levels compared to the general population; however, 
the prevalence of other metabolic abnormalities was not high. 
Analysis of patient groups based on the presence or absence of 
dyslipidemia revealed that antiretroviral therapy contributed to 
abnormality of lipid profiles; in particular, high BMI and the use 
of a PI-based regimen were statistically significant risk factor in 
multivariate analysis. To improve long-term cardiovascular out-
comes in HIV-infected Koreans, clinicians should be vigilant 
regarding the proper management of metabolic abnormalities 
in these patients.
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